Spirometric Predictors of Lung Function Decline and Mortality in Early Chronic Obstructive Pulmonary Disease

被引:102
作者
Drummond, M. Bradley [1 ]
Hansel, Nadia N. [1 ]
Connett, John E. [2 ]
Scanlon, Paul D. [3 ]
Tashkin, Donald P. [4 ]
Wise, Robert A. [1 ]
机构
[1] Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA
[2] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
[3] Mayo Clin, Dept Med, Div Pulm & Crit Care Med, Rochester, MN USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
chronic obstructive pulmonary disease; spirometry; disease progression; prognosis; mortality; RANDOMIZED CLINICAL-TRIAL; FORCED EXPIRATORY VOLUME; AIR-FLOW; HEALTH; COPD; INTERVENTION; SMOKING; BRONCHODILATOR; POPULATION; PROPIONATE;
D O I
10.1164/rccm.201202-0223OC
中图分类号
R4 [临床医学];
学科分类号
100218 [急诊医学];
摘要
Rationale: The course of lung function decline for smokers with early airflow obstruction remains undefined. It is also unclear which early spirometric characteristics identify individuals at risk for rapid decline and increased mortality. Objectives: To determine the association between spirometric measures and 5-year decline in FEV1 and 12-year mortality. Methods: We analyzed longitudinal data from the Lung Health Study, a clinical trial of intensive smoking cessation intervention with or without bronchodilator therapy in 5,887 smokers with mild to moderate airflow obstruction. Participants were stratified into bins of baseline FEV1 to FVC ratio, using bins of 5%, and separately into bins of Z-score (difference between actual and predicted FEV1/FVC, normalized to SD of predicted FEV1/FVC). Associations between spirometric measures and FEV1 decline and mortality were determined after adjusting for baseline characteristics and time-varying smoking status. Measurements and Main Results: The cohort was approximately two-thirds male, predominantly of white race (96%), and with mean age of 49 +/- 7 years. In general, individuals with lower lung function by any metric had more rapid adjusted FEV1 decline. A threshold for differential decline was present at FEV1/FVC less than 0.65 (P < 0.001) and Z-score less than -2 (2.3 percentile) (P < 0.001). At year 12, 575 (7.2%) of the cohort had died. Lower thresholds of each spirometric metric were associated with increasing adjusted hazard of death. Conclusions: Smokers at risk or with mild to moderate chronic obstructive pulmonary disease have accelerated lung function decline. Individuals with lower baseline FEV1/FVC have more rapid decline and worse mortality.
引用
收藏
页码:1301 / 1306
页数:6
相关论文
共 36 条
[1]
[Anonymous], GLOB STRAT DIAGN MAN
[2]
LUNG HEALTH STUDY [J].
ANTHONISEN, NR .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 140 (04) :871-872
[3]
Hospitalizations and mortality in the Lung Health Study [J].
Anthonisen, NR ;
Connett, JE ;
Enright, PL ;
Manfreda, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (03) :333-339
[4]
Smoking and lung function of lung health study participants after 11 years [J].
Anthonisen, NR ;
Connett, JE ;
Murray, RP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (05) :675-679
[5]
EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY [J].
ANTHONISEN, NR ;
CONNETT, JE ;
KILEY, JP ;
ALTOSE, MD ;
BAILEY, WC ;
BUIST, AS ;
CONWAY, WA ;
ENRIGHT, PL ;
KANNER, RE ;
OHARA, P ;
OWENS, GR ;
SCANLON, PD ;
TASHKIN, DP ;
WISE, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19) :1497-1505
[6]
The effects of a smoking cessation intervention on 14.5-year mortality - A randomized clinical trial [J].
Anthonisen, NR ;
Skeans, MA ;
Wise, RA ;
Manfreda, J ;
Kanner, RE ;
Connett, JE .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) :233-239
[7]
THE HORSE-RACING EFFECT AND PREDICTING DECLINE IN FORCED EXPIRATORY VOLUME IN ONE 2ND FROM SCREENING SPIROMETRY [J].
BURROWS, B ;
KNUDSON, RJ ;
CAMILLI, AE ;
LYLE, SK ;
LEBOWITZ, MD .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 135 (04) :788-793
[8]
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[9]
The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous The Experience of the BODE Cohort [J].
Casanova, Ciro ;
de Torres, Juan P. ;
Aguirre-Jaime, Armando ;
Pinto-Plata, Victor ;
Marin, Jose M. ;
Cordoba, Elizabeth ;
Baz, Rebeca ;
Cote, Claudia ;
Celli, Bartolome R. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (09) :1015-1021
[10]
CONNETT JE, 1993, CONTROL CLIN TRIALS, V14, pS3